26
|
Recker S, Voigtländer R, Viehmann A, Dunschen K, Kerp H, Frank-Raue K, Leidig-Bruckner G, Graf D, Lederbogen S, Dietrich JW, Görges R, Brabant G, Völker U, Watt T, Zwanziger D, Moeller LC, Führer D. Thyroid Related Quality of Life in Elderly with Subclinical Hypothyroidism and Improvement on Levothyroxine is Distinct from that in Young Patients (TSAGE). Horm Metab Res 2019; 51:568-574. [PMID: 31505703 DOI: 10.1055/a-0897-8785] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The aim of this study was to investigate in a longitudinal approach whether levothyroxine (LT4) substitution has a different impact on quality of life (QoL) and thyroid related QoL in younger (<40 years) and older subjects (>60 years) with elevated thyroid-stimulating hormone (TSH) concentrations. The study included male and female patients with newly diagnosed, untreated subclinical hypothyroidism defined by TSH>8 mU/l. Patients were recruited throughout Germany from 2013-2016 and evaluated by clinical assessment, blood sampling and questionnaires for health related QoL and thyroid-disease thyroid-related QoL (ThyPRO) at time of diagnosis and six months after initiation of LT4 treatment. We found significantly lower QoL in both young and old patients with subclinical hypothyroidism compared to age-matched healthy individuals. Higher scores on follow-up were found in all patients irrespective of age, indicating better QoL on LT4 therapy. Analysis of the ThyPRO questionnaire showed that old patients experienced less Emotional Susceptibility, Tiredness, and Impaired Day Life on LT4, while young patients reported less Cognitive Complaints, Emotional Susceptibility, and Impaired Day Life compared to baseline assessment. Hypothyroidism with TSH concentrations>8 mU/l is associated with impairment in general and ThyPRO QoL in young and old age. Older patients benefited from LT4 therapy and remarkably show similar degree of improvement as younger patients, albeit with some thematic variation in ThyPRO QoL. Our data confirm current recommendations on initiation of LT4 substitution and suggest that this should not be withheld in elderly with TSH concentration above 8-10 mU/l.
Collapse
|
27
|
Farahati J, Mäder U, Gilman E, Görges R, Maric I, Binse I, Hänscheid H, Herrmann K, Buck A, Bockisch A. Changing trends of incidence and prognosis of thyroid carcinoma. Nuklearmedizin 2019; 58:86-92. [PMID: 30917397 DOI: 10.1055/a-0859-7454] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
AIM to evaluate the time trend of epidemiology of follicular cell derived thyroid cancer (TC) based on data from a well documented cancer registry. METHODS Population based data on TC from Lower Franconia (LF), Germany, within 1981 and 2015 were analysed to estimate the regional epidemiology of TC. The incidence was assessed in 5-year-intervals for gender, histology, and tumor stage. RESULTS Incidence of TC solely attributable to papillary TC (PTC) doubled mainly in T1- and T2-stages within the evaluation period from 4.5 to 8.7/100.000/y in females and 1.7 to 4.1/100.000/y in males. There was no significant change of follicular TC (FTC), whereas anaplastic TC (ATC) decreased in the same interval. The number of lymph-node metastases and T3-cases increased, while the frequency of T4-stage and distant metastases decreased. Increased incidences of T1- and T2-stages suggest an over-diagnosis. In contrast, increasing number of tumors at T3-stage and with lymph node involvement contradict the over-diagnosis as the only reason for rising incidence. Declining of T4-stages in spite of increasing of T3-stages and N1-cases indicates the value of timely detection and treatment of TC. In accordance, reduced incidence of advanced cancers with M1-stage and ATC cases promote our current management of TC. CONCLUSION Timely diagnosis and adequate risk-adopted treatment of thyroid cancer reduce the frequency of high-risk cases with distant metastases and the possible protracted dedifferentiation of TC to anaplastic features. Our analyses support the management algorithm in thyroid cancer according to the recent guidelines of German Nuclear Medicine Society.
Collapse
|
28
|
Schenke S, Seifert P, Zimny M, Winkens T, Binse I, Görges R. Risk Stratification of Thyroid Nodules Using the Thyroid Imaging Reporting and Data System (TIRADS): The Omission of Thyroid Scintigraphy Increases the Rate of Falsely Suspected Lesions. J Nucl Med 2018; 60:342-347. [DOI: 10.2967/jnumed.118.211912] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 07/20/2018] [Indexed: 02/07/2023] Open
|
29
|
Schmidt M, Görges R, Drzezga A, Dietlein M. A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma? J Nucl Med 2018; 59:1195-1201. [PMID: 29748234 DOI: 10.2967/jnumed.117.191338] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2018] [Accepted: 05/03/2018] [Indexed: 12/31/2022] Open
Abstract
Radioiodine therapy is a matter of controversy because different opinions exist about its use for differentiated thyroid carcinoma. The following article sheds light on the different opinions and explains why we advocate the use of radioiodine therapy in more than only high-risk patients. In comparison to other malignancies, differentiated thyroid carcinoma has a different tumor biology due to its usually slow growth pattern. Radioiodine therapy was first used about 75 y ago and provided cure at a time when prospective randomized controlled trials had yet to be developed. Large patient cohorts and usually at least a decade of clinical follow-up are needed to demonstrate a benefit from radioiodine therapy. Thus, especially in low-risk patients, many factors define an individual treatment decision, including tumor stage, extent of surgery, tumor biology, clinical and imaging data, life expectancy, and patient preferences.
Collapse
|
30
|
Cordes U, Engelbach M, Bartelt KM, Haberern G, Hey O, Beyer J, Bockisch A, Görges R. Prädiktion der pharmakologischen Wirkung von Octreotid bei Akromegalie mittels 111In-Pentetreotid-Szintigraphie und Berechnung eines hypophysären Uptake-Index. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629870] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Zusammenfassung
Ziel: Ziel unserer prospektiven Studie war die optimierte Bestimmung des hypophysären Somatostatin-Rezeptorstatus in der 111 -In-Pentetreotid-Szintigraphie und der intraindividuelle Vergleich mit dem pharmakologischen Effekt von Octreotid bei florider Akromegalie. Methoden: Bei n = 22 Patienten mit Wachstumshormon-(GH)-sezernierendem Hypophysenadenom wurde eine 111-In-Pentetreotid-Szintigraphie durchgeführt und die spezifische Nuklidakkumulation in der Hypophysenregion (Auswertung sowohl visuell als auch semiquantitativ mittels ROI-Technik und Berechnung verschiedener Uptake-Indizes) mit dem akuten GH-Abfall nach 100 ug Octreotid s.c. (Octreotid-Akuttest) korreliert. Ergebnisse: Der von uns vorgeschlagene Uptake-Index (Quotient zirkuläre Hypophysen-ROI : irreguläre Zerebrum-ROl, jeweils cts/pixel nach Untergrund-Korrektur im sagittalen SPECT-Schnitt mit der maximalen Hypophysendarstellung 24 h p. i.) korreliert am besten mit dem pharmakologischen Effekt (akuter GH-Abfall) von Octreotid; seine obere Normgrenze liegt im Bereich von 3,5. Schlußfolgerungen: Da sich häufig auch die normale Hypophyse szintigraphisch darstellen läßt, ist die rein visuelle Abgrenzung zum pathologischen Rezeptorstatus manchmal uneindeutig. Ein mittels standardisierter ROI-Technik berechneter, hypophysärer Uptake-Index erleichert diese Abgrenzung und hilft so, mögliche Responder für eine Octreotid-Langzeittherapie zu selektieren.
Collapse
|
31
|
Kahaly G, Müller-Brand J, Mäcke H, Walgenbach S, Bruns C, Andreas J, Brandt-Mainz K, Bockisch A, Görges R. Untersuchungen zum Somatostatinrezeptor-Status bei nicht-medullären Schilddrüsenkarzinomen. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632183] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Zusammenfassung
Ziel: In aktuellen ln-vitro- und In-vivo-Untersuchungen wurde eine Somatostatinrezeptor-Expression bei einigen nicht-medullären Schilddrüsenkarzinomen nachgewiesen. In der vorliegenden Studie wird der Somatostatinrezeptor-Status bei dieser Tumorentität in einem größeren Patientenkollektiv untersucht. Patienten und Methoden: Wir verglichen 131-lod- mit 111-ln-Pentetreotide-Szintigraphien bei 24 Patienten mit metastasiertem, nicht-medullären Schilddrüsenkarzinom. Die Befunde wurden mit anderen bildgebenden Verfahren korreliert. Zusätzlich erfolgten Rezeptor-Autoradiographien bei einem Patienten, eine Octreotide-Behandlung bei einem anderen und die Verabreichung von 90-Y- sowie 111-ln-DOTATOC bei zwei weiteren Patienten. Ergebnisse: Bei 8/15 Patienten mit papillärem oder follikulärem Schilddrüsenkarzinom erwies sich 111-ln-Pentetreotide dem 131-I als unterlegen, bei 1/15 als gleichwertig und bei 6/15 als überlegen. Bei 8/9 Patienten mit onkozytärem Schilddrüsenkarzinom zeigten die Metastasen eine 111-ln-Pentetreotide-Akkumulation unterschiedlicher Intensität, während die 131-l-Szintigraphien hier bis auf eine Ausnahme negativ waren. Im Vergleich mit 201-Tl oder 99m-Tc-Sestamibi erwies sich 111-ln-Pentetreotide als gleichwertig oder überlegen, aber im Vergleich zum 18-FFDG-PET zumeist als unterlegen. Die Befunde der 111-ln-Pentetreotide-Szintigraphie korrelierten gut mit der Rezeptor-Autoradiographie und der DOTATOC-Akkumulation, nicht dagegen mit dem Behandlungseffekt von »kaltem« Octreotide auf die Schilddrüsenkarzinom-Metastasen. Schlußfolgerungen: Diverse Metastasen papillärer und follikulärer Schilddrüsenkarzinome und die Mehrzahl der onkozytären Schilddrüsenkarzinom-Metastasen können Somatostatin-Rezeptoren exprimieren. Insbesondere beim onkozytären Schilddrüsenkarzinom beziehungsweise bei nicht verfügbarem PET erweist sich die 111-ln-Pentetreotide-Szintigraphie als vielversprechende Methode zur Metastasenlokalisation; sie könnte ferner von Nutzen sein bei der Selektion möglicher Kandidaten für eine Therapie mit ß-Strahler-markierten Somatostatinanaloga, wenn diese für die klinische Routine verfügbar sind.
Collapse
|
32
|
Eißner D, Kahaly G, Voges E, Kersjes W, Bockisch A, Görges R. Darstellung von Metastasen eines Schilddrüsenkarzinoms mittels 111In-Pentetreotide-Szintigraphie. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629820] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
ZusammenfassungZur Darstellung von Schilddrüsenkarzinomgewebe mittels Somatostatin-Rezep-torszintigraphie liegen bisher wenig Erfahrungen vor. Wir stellen die Kasuistik einer akromegalen Patientin vor, bei der die 111 In-Pentetreotide-Szintigraphie -außer einem Somatostatinrezeptor-positiven Hypophysentumor - auch Metastasen eines papillären Schilddrüsenkarzinoms darstellte, die im unter Hypothyreose angefertigten Radiojodszintigramm kein Korrelat fanden. Der mögliche Stellenwert dieses Radiopharmazeutikums bei entdifferenzierenden Schilddrüsenkarzinomen wird in bezug auf den lokalisationsdiagnostischen Nutzen sowie auf die prädiktive Aussagekraft hinsichtlich des Erfolges einer Octreotide-Langzeit-behandlung diskutiert.
Collapse
|
33
|
Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Otterbach F, Freudenberg LS. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary:Aims: c-erbB-2 overexpression has been shown to be a potential marker of aggressive biological behaviour in a varity of tumours, whereas its role played in thyroid papillary thyroid carcinoma (PTC) remains unclear. Objective of the study is to determine whether c-erbB-2 overexpression correlates with the clinical course. Methods: We have studied 32 PTC by a two-step immunocytochemical staining procedure for paraffin-embedded specimens (DAKO Hercep- Test). Semiquantitative evaluations were performed, based on the intensity of immunostaining and the percentage of tumor cells. Results: 34% (11/32) of the PTC showed a membranous overexpression of the HER2/neu oncoprotein. Correlating the pathological and clinical data revealed that 81% (9/11) c-erbB-2 positive patients and only 33% (7/21) c-erbB-2 negative patients developed a tumor recurrence or a progression (p = 0.02 in Fisher’s exact test). 3/11 c-erbB-2 positive patients died from PTC whereas all (21/21) c-erbB-2 negative patients are still alive (p=0.03). Conclusions: Our results strongly suggest that c-erbB-2 oncoprotein overexpression is related to the clinical course of PTC.
Collapse
|
34
|
Brandt-Mainz K, Freudenberg L, Frilling A, Grimm W, Bockisch A, Görges R. Kontinuierliche Sensitivitätssteigerung in der Schilddrüsenkarzinom-Nachsorge im Verlauf dreier Thyreoglobulin-IMA-Generationen. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625185] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary:
Aim of our study was to evaluate the increasing sensitivity within three generations of thyroglobulin (Tg) as-says, which were available during the past decade, and its clinical impact for patients with differentiated thyroid carcinoma. Methods: Determination of Tg using the IRMA introduced in 1989 (Dynotest®Tg, Henning Berlin, Berlin; assay A) and 1994 (Selco®Tg, Medipan Diagnostica, Selchow; assay B), as well as the IEMA available recently (Medizym®Tg Rem, Medipan Diagnostica, Selchow; assay C). Results: We found a close correlation between the measurable Tg values of assay A and B (r = 0.985; p <0.001) as well as assay B and C (r = 0.978; p <0.001). Assay B (lowest detection limit: 0.3 ng/ml) was more than twice as sensitive as assay A and did not show quite as many disturbances of recovery (in 0.5% versus 4% of our patients). Due to its strict calibration to the European reference preparation CRM 457, Tg values determined by assay C were in the mean 1.9-fold higher than by assay B. Thus, with its functional sensitivity of 0.03 ng/ml assay C is nearly 20-fold more sensitive than assay B. Whereas the proportion of measurable Tg values was only 22% in a selected group of patients (criterion of inclusion: Tg in assay B ≤1 ng/ml with TSH-suppressive conditions; n = 317 serum samples from 103 patients), it was 68% in assay C, with good intraindividual reproducibility of these values in the course. Conclusion: The ultrasensitive assay C is especially suitable for the follow-up of treated thyroid cancer patients being considered as cured, and may shorten the time interval until the detection of a recurrence markedly: the gain of time calculated from the Tg courses in patients with a gradually progressive tumor relapse ranged from 5 to 15 months.
Collapse
|
35
|
Beyer T, Müller SP, Görges R, Hopfenbach A, Bockisch A, Freudenberg LS. Evil radioactivity. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625225] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary:Aim: We assess the perspective of patients with thyroid disease towards radiation and radioactivity by means of a cultural- anthropological approach based on qualitative measures and quantitative scores. From the interviews with the patients we evaluate as to how much radioactivity is accepted as an abstract term or as a benefit within the medical context. Patients, methods: 68 patients with autonomously functioning thyroid lesions (35 women, 33 men, 32-81 years) were included in this study. All patients were interviewed in an open dialogue with the principal investigator. Patients were asked to describe their attitude towards radioactivity in general and towards radioiodine therapy in particular. Patients were asked to use a scoring system (1 = positive, 5 = negative) to quantify their attitudes. Results: The responses of all patients towards radioactivity in general were heterogeneous with most responses reflecting a negative perception. Many patients expressed their associated fears about atomic energy, malignant diseases and radioactive contamination. The scoring system reflected a mostly negative opinion base. However, patients became more positive once they assumed an immediate benefit of radioactivity for the treatment of their own disease (p = 0.01). Conclusions: Knowing about significant differences in patient’s perception about radioactivity in general or in the clinical context may help to optimise and tailor the initial, pre-therapeutical interview towards the patient.
Collapse
|
36
|
Gauler T, Görges R, Bauer S, Stergar H, Antoch G, Bockisch A, Schütte J, Freudenberg LS. Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Nuklearmedizin 2018. [DOI: 10.3413/nukmed-0119] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
SummaryAims: Objective of this prospective study was to evaluate the role of somatostatin receptor scintigraphy (SRS) in advanced renal cell carcinoma (RCC) with respect to potential therapy with somatostatin analogue (SST-A) and to assess the response rate under therapy with SST-A. Patients, methods: 16 patients with documented progression of histologically confirmed advanced RCC were included. Planar whole-body SRS was performed 4, 24 and 48h post i.v. injection of 175–200 MBq 111In-pentetreoide. 5 and 25 h p.i. SPECT of thorax and abdomen were performed. Documentation of somatostatin receptor expression via SRS in >50% of known tumour lesions was the criteria for treatment start with SST-A (Sandostatin LAR®-Depot 30mg i.m. every four weeks). Results: In 9/16 of the patients SRS showed at least one metastasis with moderate (n = 5) or intense (n = 4) tracer uptake. Lesion-based SRS evaluation showed only 12.1% (20/165) of all metastases. Most false-negative lesions were located in the lungs. In two patients, the majority of the known metastases was SRS positive and these patients received SST-A therapy. The first radiographic evaluation after a twomonth interval showed progressive disease in both patients. Conclusions: We conclude that SRS is of limited value in staging of advanced RCC. In our patients SST-A did not result in a growth control of RCC. Consequently, the use of SST-A in advanced RCC seems to be no relevant therapeutic option.
Collapse
|
37
|
Farahati J, Görges R, Grabellus F, Bockisch A, Sheu-Grabellus SY, Nagarajah J. Success rate of repeated fine needle aspiration biopsy of clinically suspicious thyroid nodules. Nuklearmedizin 2017; 51:116-8. [DOI: 10.3413/nukmed-0472-12-01] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2011] [Accepted: 04/20/2012] [Indexed: 11/20/2022]
Abstract
SummaryIn this study we evaluated the success rate of double fine needle aspiration biopsy (FNAB) of clinically suspicious thyroid nodules in one session. Aim: The success rate of FNAB in clinical setting is quite low. There were several attempts made to improve the success rate of this method. It is anticipated that a double FNAB in one session would increase the success rate of FNAB. Patients, methods: 176 consecutive patients (130 women, 46 men; mean age 56 years ± 11) with at least one clinically suspicious nodule were included in this study. Each individual nodule was biopsied twice (20G- and 21G-needle). In 33 patients, two suspicious nodules were biopsied, accounting for a total of 209 biopsied thyroid nodules. To evaluate the success rate the number of cell formations and the total number of cells in each cell formation were counted. Results: The biopsy with the 20G needle provided in mean 40 cell cluster with a mean of 830 cells niedwhereas the 21G needle provided in mean 41 cell cluster with a mean of 1010 cells. With the 20G needle the success rate was 73%, with the 21G needle 78% and the combination of the both biopsies provided a success rate of 87% (p = 0.01). Based on the number of cell formations and the total number of cells, the difference between the two needle sizes was not significant (p = 0.5 for cell formations and p = 0.9 for the total number of cells, respectively). Conclusion: A double FNAB of suspicious thyroid nodules in one session provides a higher success rate, and a 21G needle is sufficient enough.
Collapse
|
38
|
Moldovan AS, Ruhlmann M, Görges R, Bockisch A, Rosenbaum-Krumme S, Jentzen W. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Nuklearmedizin 2017; 54:137-43. [DOI: 10.3413/nukmed-0711-14-12] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 02/17/2015] [Indexed: 12/13/2022]
Abstract
SummaryAim: A theoretical dosimetry-based model was applied to estimate the lowest effective radioiodine activity for thyroid remnant ablation of low-risk differentiated thyroid cancer patients. Patients, methods: The model is based on the distribution of the absorbed (radiation) dose per administered radioiodine activity and the absorbed dose threshold of 300 Gy for thyroid remnants, the level believed to destroy most thyroid remnants. For this purpose, 124I PET/CT images of 49 thyroid-ectomised patients were retrospectively analysed to measure the distribution of the (average) absorbed doses to thyroid remnant per administered 131I activity. The fraction of thyroid remnants that received at least 300 Gy was determined for standard activities between 0.37 and 5.55 GBq. The lower activity was considered to be equally effective to that obtained with higher activity if the (absolute) fraction difference was below 5%. Results: A total of 62 thyroid remnants were included. The medians and ranges (in parentheses) for the absorbed dose per unit 131I activity were 359 Gy/GBq (34 to 1825 Gy/ GBq). The fractions of thyroid remnants receiving more than 300 Gy at different therapy activities (within parentheses) were 60% (1.11 GBq), 76% (1.85 GBq), 79% (2.22 GBq), and 81–82% for activities between 2.59 and 3.70 GBq. The therapy activity of 1.11 GBq is considerably less effective than that of 1.85 or 2.22 GBq; therapy activities were equally effective in the range between 2.22 to 3.70 GBq. Conclusion: On the basis of the model and the patients' data included, the lowest effective therapy activity appears to be approximately 2.2 GBq to ablate thyroid remnants. The results of this study may help to guide the design of prospective clinical studies.
Collapse
|
39
|
Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A, Freudenberg LS. 124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact. Nuklearmedizin 2017. [DOI: 10.1160/nukmed-0076] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Summary
Purpose: This study evaluated the impact of 124I-positron emission tomography (PET) dosimetry on post-primary surgery therapy in radioiodine-naive patients with advanced differentiated thyroid cancer (DTC). Patients, material, methods: In each of 28 thyroidectomized patients with high-risk DTC (one or more of pT4, pN1 or pM1), we gave 23.50 MBq of 124I as an oral capsule and performed PET dosimetry to calculate the individualized therapeutic 131I activity that would, insofar as possible, achieve a radioiodine dose ≥100 Gy to all metastases without exceeding 2 Gy to the blood (a surrogate for bone marrow toxicity). We thus determined the absorbed lesion dose per GBq of administered 131I activity (LDpA) based on serial PET (4, 24, 48, 72 and 96 h after oral 124I intake) and PET/computed tomography (25 h after 124I intake) and the critical blood activity (CBA) based on blood and whole-body radiation counting (2, 4, 24, 48, 72, 96 h after 124I intake). We compared the dosimetry-based interventions with our standard empirical protocol. Results: 25 patients had a total of 126 iodine-positive metastases. 18 (72%) of the 25 had solely iodine-avid metastases, while seven (28%) had both iodine- avid and -non-avid metastases. In two patients (8%), none of the iodine-avid metastases could have been practically treated with a sufficient radiation dose. Relative to the empirical protocol, 124I-PET dosimetry findings changed management in 7 (25%) patients, e. g. allowing application of activities >11 GBq 131I. Further changes included implementation of hematological back-up in a patient found to be at risk of life-threatening marrow toxicity, and early multimodal therapy in 9 (32%) patients. Conclusion: 124I-PET dosimetry is a useful routine procedure in advanced DTC and may allow safer or more effective radioiodine activities and earlier multimodal interventions than do standard empirical protocols.
Collapse
|
40
|
Sheu-Grabellus SY, Leitzen C, Hartung V, Schmid KW, Bockisch A, Görges R, Nagarajah J. Optimierung der Schilddrüsen- Feinnadelpunktion. Nuklearmedizin 2017; 50:189-94. [DOI: 10.3413/nukmed-0387-11-02] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2011] [Accepted: 06/07/2011] [Indexed: 11/20/2022]
Abstract
SummaryObjective: Optimization of a specially developed automatic microaspirator for fine-needle aspiration of suspicious thyroid nodules. Patients, method: In a preliminary test biopsy effectiveness was evaluated in 20 native resected thyroid glands in vitro with both a Cameco® gun and a specially designed microaspirator respectively. In addition in both techniques two different needles (21-G and 27-G) were used to evaluate the influence of these two cannula. Subsequently, 103 thyroid nodules were biopsied in vivo and compared the results with a preliminary series of the same physician. In the workup and evaluation of the cytology the ThinPrep® technology was used. Results: In vitro the automatic microaspirator was superior to Cameco gun in both when using the 21-Gauge and the 27-Gauge needle. In terms of needle sizes a statistically significant difference at the 95% confidence level was evident for both comparisons in favor of 21-gauge needle. In vivo, 91% of punctures with the microaspirator were usable, while in the pre-series only 84% were usable (p > 0.05). Conclusion: The automatic microaspirator is superior to the manual aspiration. Moreover, under sonographic control it is more convenient, to biopsy even very small nodules and lesiosn (down to 4 mm in diameter)
Collapse
|
41
|
Ruhlmann M, Ruhlmann J, Görges R, Herrmann K, Antoch G, Keller HW, Ruhlmann V. 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography May Exclude Malignancy in Sonographically Suspicious and Scintigraphically Hypofunctional Thyroid Nodules and Reduce Unnecessary Thyroid Surgeries. Thyroid 2017; 27:1300-1306. [PMID: 28793848 DOI: 10.1089/thy.2017.0026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND The aim of this study was to evaluate whether 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is useful in the further characterization of sonographically suspicious and scintigraphically hypofunctional thyroid nodules. METHODS Sixty-five patients with sonographically suspicious thyroid nodules that were hypofunctional on 99m-Tc-pertechnetate scintigraphy (diameter >1 cm) were retrospectively analyzed. All patients underwent evaluation with FDG-PET/CT. Thyroid nodules were sonographically categorized by Thyroid Image Reporting and Data System (TIRADS) criteria. FDG uptake in the thyroid nodules was visually compared to the remainder of the thyroid tissue and categorized as pathological or non-pathological. In cases of pathologically increased uptake, maximum standardized uptake values (SUVmax) of the suspicious nodule and the perinodular thyroid tissue were determined. Depending on the results of the FDG-PET/CT, patients underwent thyroid surgery (pathological FDG uptake) or follow-up examinations (non-pathological FDG uptake). The endpoints for comparison with the FDG uptake were either histological results or sonographic follow-up examinations of at least five years. RESULTS In 18/65 (28%) patients, PET/CT showed visually pathological FDG uptake in the suspicious thyroid nodules (SUVmax 7.1 ± 4.6). Of these nodules, 3/18 (17%) were sonographically categorized as TIRADS 4a, 11/18 (61%) nodules as TIRADS 4b, 3/18 (17%) nodules as TIRADS 4c, and 1/18 (6%) nodule as TIRADS 5. The other nodules without pathological FDG uptake were categorized as TIRADS 4a in 24/47 (51%) patients, as TIRADS 4b in 18/47 (38%), and as TIRADS 4c in 5/47 (11%) patients. Twenty-three patients (18 FDG positive, 5 FDG negative) underwent surgery. The other patients underwent follow-up examinations with stability on observation over at least five years as a surrogate endpoint. Taking into consideration that FDG-PET/CT was rated as true negative in 42/47 patients with stability on sonographic follow-up, sensitivity, specificity, positive predictive value, and negative predictive value of FDG-PET/CT in detecting malignancy in the suspicious thyroid nodules were 100%, 87%, 61%, and 100%, respectively. CONCLUSION FDG-PET/CT allows stratification of patients with sonographically suspicious and scintigraphically hypofunctional thyroid nodules with a positive predictive value of 61% and negative predictive value of 100%. The absence of visually pathological FDG uptake in suspicious thyroid nodules may be useful for avoiding unnecessary thyroid surgery.
Collapse
|
42
|
Rössing RM, Jentzen W, Nagarajah J, Bockisch A, Görges R. Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer. Thyroid 2016; 26:1712-1718. [PMID: 27750024 DOI: 10.1089/thy.2016.0031] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Tumor marker doubling time (DT) has been proposed as a prognostic marker for various types of cancer. The present study analyzed the DT of the thyroid-specific tumor marker thyroglobulin (Tg), focusing on patients with progressive differentiated thyroid cancer (DTC). METHODS A total of 144 Tg courses of 99 patients with progressive or recurrent DTC were included (median observation period 19 months, 3-11 Tg measurements per course) in this retrospective study. The distribution of Tg-DT was determined for both a highly sensitive assay (functional working range 0.03-3 ng/mL) and a routine assay. Tg-DT and other prognostic markers were used to perform uni- and multivariate statistical analyses for survival predictors. RESULTS The median Tg-DT was 212 days (95% percentile: 49-961 days). No significant differences were observed between DT derived from Tg values in the very low range using a highly sensitive assay and DT calculated from Tg values measured by a conventional Tg assay. Multivariate analysis yielded no simple correlation between Tg-DT and survival rate, but the mortality risk of patients with a Tg-DT <5 months was more than twice as high as compared with a Tg-DT of >14 months. Highly significant differences on survival rates were only observed in patients with a high tumor load (Tg >100 ng/mL). CONCLUSIONS Tg-DT alone is not an independent survival predictor in all patients with progressive DTC; however, analyzing only patients with a high tumor load, we found highly significant differences in survival rates.
Collapse
|
43
|
Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer. Eur J Nucl Med Mol Imaging 2016; 43:1988-94. [DOI: 10.1007/s00259-016-3400-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 04/13/2016] [Indexed: 02/08/2023]
|
44
|
Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, Beiderwellen K, Bockisch A, Rosenbaum-Krumme SJ. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin. J Nucl Med 2016; 57:1512-1517. [DOI: 10.2967/jnumed.115.171942] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2015] [Accepted: 02/29/2016] [Indexed: 12/31/2022] Open
|
45
|
Broecker-Preuss M, Baten J, Sheu-Grabellus SY, Görges R, Bockisch A, Schmid KW, Führer D, Mann K. Expression of the cAMP binding protein EPAC1 in thyroid tumors and growth regulation of thyroid cells and thyroid carcinoma cells by EPAC proteins. Horm Metab Res 2015; 47:200-8. [PMID: 25372777 DOI: 10.1055/s-0034-1390484] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The thyrotropin receptor-cAMP pathway is central in growth regulation of thyroid cells and thyroid tumorigenesis, and it regulates expression of thyroid specific genes. Recently, 2 new protein kinase A-independent cAMP effectors named EPAC1 and 2 were described that activate additional intracellular pathways. The aim of our study was to investigate the role of EPAC proteins in growth regulation of thyroid cells and thyroid carcinomas. EPAC1 expression was investigated immunohistochemically in tissues of various thyroid tumors. Utilizing MTT assay, the effect of EPAC stimulation on proliferation in thyroid carcinoma cells and in non-transformed rat FRTL5 cells was investigated. The activation of intracellular signaling pathways was examined by RAP pull-down assay and Western blots. EPAC1 expression was strong in non-oxyphilic follicular thyroid adenomas and carcinomas and in follicular papillary thyroid carcinomas. It was moderate in oxyphilic follicular tumors and classical and tall cell papillary carcinomas. In contrast, EPAC1 expression was low in poorly differentiated carcinomas and very low in anaplastic carcinomas. Thyroid carcinoma cell lines showed no or very weak EPAC1 expression and exhibited no growth-promoting effect after EPAC stimulation. Non-transformed rat FRTL5 cells were growth-stimulated by an EPAC-specific cAMP-analogue and showed EPAC-dependent activation of RAP, ERK, and p70S6 kinase. EPAC1 expression and cellular response to EPAC activation in rat FRTL5 cells reflect cellular responses to cAMP and TSH stimulation in non-transformed thyroid cells. In undifferentiated thyroid carcinomas, loss of EPAC1 expression may be in accordance with the loss of thyroid-specific functions and the loss of responsiveness of the TSHR-cAMP pathway.
Collapse
|
46
|
Ruhlmann M, Stebner V, Görges R, Farahati J, Simon D, Bockisch A, Rosenbaum-Krumme S, Nagarajah J. Diagnosis of hyperfunctional thyroid nodules: impact of US-elastography. Nuklearmedizin 2014; 53:173-7. [PMID: 24898434 DOI: 10.3413/nukmed-0660-14-04] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Accepted: 05/26/2014] [Indexed: 12/16/2022]
Abstract
AIM Several studies described the ultrasound based real-time elastography (USE) having a high sensitivity, specificity and negative predictive value in the diagnosis of suspicious thyroid nodules. Recently published studies called these results into question. Until now the usefulness of USE in the diagnosis of scintigraphically hyperfunctional thyroid nodules is not examined. PATIENTS, METHODS This study included 135 hyperfunctional thyroid nodules of 102 consecutive patients. The following attributes of the nodules were analyzed: stiffness with the USE using scores of Rago or Asteria and ultrasound criteria using TIRADS. RESULTS 94 of the examined thyroid nodules (70%) were rated as hard (suspicious for malignancy) and 41 nodules (30%) as soft (not suspicious) with a specificity of 30%. The scoring systems of Rago and Asteria showed no significant difference. Applying the TIRADS criteria 44 nodules (33%) have a higher risk for malignancy (33 nodules TIRADS 4a, 11 nodules TIRADS 4b). Combining USE and TIRADS 32 nodules (24%) are categorized as suspicious (intersection of hard nodules that are categorized as TIRADS 4a or 4b). CONCLUSION Ultrasound based real-time elastography cannot identify scintigraphically hyperfunctional thyroid nodules as benign nodules reliably. Its accuracy in the assessment of at least "hot" thyroid nodules is to be questioned.
Collapse
|
47
|
Lodemann E, Bockisch A, Görges R. Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving. Psychoneuroendocrinology 2012; 37:1726-35. [PMID: 22541716 DOI: 10.1016/j.psyneuen.2012.03.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Revised: 03/05/2012] [Accepted: 03/06/2012] [Indexed: 10/28/2022]
Abstract
CONTEXT In patients with differentiated thyroid carcinoma (DTC) who, after thyroidectomy, are to receive radioiodine therapy or diagnostics, a strong TSH stimulus is necessary. Traditionally, this is induced by thyroid hormone withdrawal (THW) over a period of 4-5weeks; alternatively thyroid hormone replacement therapy is continued and recombinant human thyrotropin (rhTSH) is administered. During the hypothyroid state due to THW, patients often report mood disturbances and physical complaints but also an impairment of performance during attention demanding tasks. OBJECTIVE Based on physiological, self-report and performance test data collected from various studies, we proposed the hypothesis that thyroidectomized DTC patients perform significantly worse in cognitive-motor functions that are relevant for driving when in the THW-induced hypothyroid state compared to when thyroid hormone replacement therapy is continued and rhTSH is administered. METHODS We compared 41 DTC patients (age 42.3 (9.4) years; 80.5% female) after 4weeks THW with 41 DTC patients after the application of rhTSH, pairwise matched according to age, gender and educational level, with respect to performance in 4 core tests of the Act-React-Testsystem ART-90, a validated test battery for examining fitness to drive. RESULTS Contrary to our expectations, no statistically relevant impairment of performance could be confirmed in the THW group in comparison to the rhTSH group for any variable (at adjusted α). At most there is a tendency in the THW group for slowed reaction times in simple-choice reaction tasks; the (standardized) difference to the rhTSH group is however small (d'=0.31). Furthermore, large effects due to THW, as they are suggested by several studies, could be excluded.
Collapse
|
48
|
Nagarajah J, Sheu-Grabellus SY, Farahati J, Kamruddin KA, Bockisch A, Schmid KW, Görges R. Ultrasound-guided fine-needle aspiration biopsy of clinically suspicious thyroid nodules with an automatic aspirator: a novel technique. Thyroid 2012; 22:695-8. [PMID: 22524469 DOI: 10.1089/thy.2011.0182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Fine-needle aspiration biopsy (FNAB) is a simple technique for the investigation of suspicious thyroid nodules. However, low success rates are reported in the literature. The aim of this prospective study was to compare the clinical performance and impact of an automatic aspirator, referred to here as Aspirator 3, to those of the manual technique for the FNAB of clinically suspicious thyroid nodules. METHODS One hundred nine consecutive patients with 121 clinically suspicious thyroid nodules underwent a biopsy twice of the same site with the clinically approved Aspirator 3 and with the manual technique. The number of follicular cell formations and the total number of follicular cells in the aspirate were counted using the ThinPrep® method. RESULTS With the Aspirator 3, the total number and the mean number of extracted cell formations were significantly higher than the values achieved with the manual technique (total: 3222 vs. 1951, p=0.02; mean: 27 vs. 16). The total number of cells that were biopsied was also higher when the Aspirator 3 was utilized (47,480 vs. 23,080, p=0.005). Overall, the Aspirator 3 was superior in 65 biopsies, and the manual technique was superior in 39 biopsies. CONCLUSIONS In terms of cell formations and the total number of cells aspirated, the Aspirator 3 was superior to the manual technique. Further, the Aspirator 3 was more convenient to use and had a greater precision in needle guidance.
Collapse
|
49
|
Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012; 39:1373-80. [PMID: 22718304 DOI: 10.1007/s00259-012-2065-4] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Accepted: 01/05/2012] [Indexed: 11/28/2022]
Abstract
PURPOSE Advanced tumour stage and initial metastases are associated with reduced general and tumour-free survival in patients with differentiated thyroid carcinoma. Optimal initial therapy is mandatory for a positive patient outcome, but can only be performed if all non-iodine-avid tumour lesions are known before planning treatment. We analysed the benefit of (18)F-FDG PET/CT at initial diagnosis in patients with high-risk differentiated thyroid carcinoma and determined whether the (18)F-FDG PET/CT results led to a deviation from the standard procedure, which consists of two consecutive radioiodine treatments with thyroid hormone suppression in between and no additional imaging, with individual patient management. METHODS The study group comprised 90 consecutive patients with either extensive or metastasized high-risk differentiated thyroid carcinoma who received (18)F-FDG PET/CT after the first radioiodine treatment approximately 4 weeks after thyroidectomy under endogenous TSH stimulation. We carried out PET/CT imaging with low-dose CT without contrast medium, which we only used for attenuation correction of PET images. RESULTS (18)F-FDG PET/CT was positive in 26 patients (29%) and negative in 64 patients (71%). Compared to the results of posttherapeutic (131)I whole-body scintigraphy, the same lesions were PET-positive in 7 of the 26 patients, different lesions were PET-positive in 15 patients, and some PET-positive lesions were the same and some were different in 4 patients. TNM staging was changed due to the PET results in 8 patients. Management was changed in 19 of the 90 patients (21%), including all patients with only FDG-positive lesions and all patients with both FDG-positive and iodine-positive lesions. Age was not a predictive factor for the presence of FDG-positive lesions. FDG-positive and iodine-positive lesions were associated with high serum thyroglobulin. However, at low serum thyroglobulin values, tumour lesions (iodine- and/or FDG-avid) were also diagnosed. Thus, the serum thyroglobulin value prior to the first radioiodine treatment cannot be used as a predictor of the presence of FDG-positive lesions. CONCLUSION (18)F-FDG PET/CT resulted in a change of therapeutic procedure in 11 of 90 patients and in a change of patient management through additional diagnostic measures in 8 of 90 patients, and is consequently very helpful in initial staging. At our hospital, (18)F-FDG PET/CT in high-risk patients with differentiated thyroid carcinoma has been established as an initial staging modality.
Collapse
|
50
|
Müller S, Nagarajah J, Lahner H, Broecker-Preuss M, Bockisch A, Görges R, Hartung-Knemeyer V. Assay-Abhängigkeit der Calcitonin- Zielbereiche für „biochemisch geheilte“ Patienten mit medullärem Schilddrüsenkarzinom. Nuklearmedizin 2012; 51:125-32. [DOI: 10.3413/nukmed-0454-11-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Accepted: 03/30/2012] [Indexed: 11/20/2022]
Abstract
SummaryAim: Calcitonin (hCT) is an important diagnostic parameter in medullary thyroid carcinoma (MTC). We determined the variability of the reference ranges of several currently available immunometric assays for „biochemically cured“ MTC patients. Patients, methods: We compared six assays [Nichols ICMA, Biomerica IEMA, Immulite 2000 (Siemens), Calcitonin-IRMA magnum (Medipan), SELco-IRMA (Medipan) and Calcitonin IRMA (Medgenix)] in subgroups of 198 patients with differentiated thyroid cancer (DTC) after total thyroidectomy as a model for curatively treated MTC patients. In addition, hCT was measured after pentagastrin stimulation in 13 DTC patients and 13 patients with MTC. Results: The basal hCT concentrations were below the detection limit of the respective assay in 100% of all thyroidectomized DTC patients for Nichols ICMA (n = 138) and Immulite 2000 (n = 60), in 97% for Biomerica IEMA (n = 57), and in 85% for IRMA magnum (n = 20). However, basal hCT was mostly within the reference range in Selco-IRMA (n = 20) and Medgenix IRMA (n = 76). In all DTC patients and 9/13 MTC patients the pentagastrin stimulated hCT was below the detection limit for the Nichols ICMA and Immulite 2000, all four MTC patients with elevated stimulated hCT developed a recurrence during follow-up. Conclusions: For assays with high monomer specificity (Nichols ICMA, Biomerica IEMA, Immulite 2000, to a lesser degree IRMA magnum) biochemical cure is defined by basal and stimulated calcitonin levels below the detection limit. For assays with low monomer specificity (SELco-IRMA, IRMA Medgenix) calcitonin levels in the reference range of patients without thyroid diseases are consistent with “biochemical cure”.
Collapse
|